Skip to main content

Table 1 Main Characteristics of the study population

From: Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV

Characteristics Total
  N = 486
Gender, n (%)
Female 139 (28.6%)
Age, years, median (range) 37 (18, 74)
Mode of HIV transmission, n (%)
Homosexual contacts 128 (26.3%)
Heterosexual contacts 232 (47.5%)
IDU 103 (21.2%)
Other/unknown 23 (4.7%)
CD4 count, cells/mmc, median (range) 256 (21180)
CD4 nadir, cell/mmc, median (IQR) 242 (121–336)
Viral load, log10 copies/mL, median (IQR) 4.8 (4.1, 5.2)
Hepatitis co-infection, n (%)
Negative 176 (36.1%)
Positive 97 (19.9%)
Not tested 215 (44.1%)
Time from HIV diagnosis to cART, months Median (IQR) 44 (38, 50)
Calendar year of starting cART, median (range) 2003 (1998, 2010)
Clinical Follow-up timea, months Median (IQR) 79.0 (30.0, 134.0)
  1. Note: IQR Interquartile range, IDU Injection drug users, cART Combination of antiretroviral therapy. aClinical follow-up time: time between cART initiation and the clinical event or for those who did not develop any of the endpoint-defining events, time between cART initiation and last CD4 count or available visit